FrancophonIA/ELRC3.0 huggingface dataset:
English: Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A).
Croatian: Ranibizumab je fragment humaniziranog rekombinantnog monoklonskog antitijela na ljudski čimbenik rasta vaskularnog endotela A (VEGF-A).
English: - Macular oedema (swelling of the centre of the retina).
Croatian: - Makularnim edemom (oticanjem središnjeg dijela mrežnice).
English: Less frequently reported, but more serious, adverse reactions include endophthalmitis, blindness, retinal detachment, retinal tear and iatrogenic traumatic cataract (see section 4.4).
Croatian: Manje učestalo prijavljene, ali ozbiljnije nuspojave uključuju endoftalmitis, sljepoću, ablaciju mrežnice, razderotinu mrežnice i jatrogenu traumatsku kataraktu (vidjeti dio 4.4).
English: Lucentis can be used for people of 65 years of age and over without dose adjustment.
Croatian: Starije osobe (65 godina starosti i više) Osobe od 65 godina starosti i više mogu primati Lucentis bez prilagođavanja doze.
English: Limited data from sham subjects who later received ranibizumab suggested that early initiation of treatment may be associated with better preservation of visual acuity.
Croatian: Ograničeni podaci dobiveni od ispitanika liječenih placebo postupkom koji su kasnije primili ranibizumab ukazuju da se rani početak liječenja može povezati s boljim očuvanjem vidne oštrine.
English: Children and adolescents (below 18 years of age) The use of Lucentis in children and adolescents has not been established and is therefore not recommended.
Croatian: Djeca i adolescenti (mlađi od 18 godina starosti) Primjena Lucentisa u djece i adolescenata nije ustanovljena te se stoga ne preporučuje.
English: In preterm infants treatment of retinopathy of prematurity (ROP) is initiated with a single injection per eye and may be given bilaterally on the same day.
Croatian: U prijevremeno rođene dojenčadi se liječenje retinopatije nedonoščadi (ROP) započinje jednom injekcijom po oku i može se primijeniti obostrano istoga dana.
English: - If your baby has an infection in or around the eye. - If your baby has pain or redness (severe intraocular inflammation) in the eye.
Croatian: - Ako Vaše dijete ima infekciju u ili oko oka.
English: For ranibizumab no clinical data on exposed pregnancies are available.
Croatian: Nema kliničkih podataka o primjeni ranibizumaba u trudnoći.
English: ADULTS
Croatian: Odrasli
English: Adults
Croatian: ODRASLI
English: Dispose of the used syringe together with the needle in a sharps disposal container or in accordance with local requirements.
Croatian: Odložite upotrijebljenu štrcaljku zajedno s iglom u spremnik za oštre predmete sukladno lokalnim propisima.
English: In clinical studies for the treatment of visual impairment due to DME, the outcome with regard to visual acuity or central retinal subfield thickness (CSFT) in patients treated with Lucentis was not affected by concomitant treatment with thiazolidinediones.
Croatian: U kliničkim ispitivanjima za liječenje oštećenja vida uzrokovanog DME-om, ishod s obzirom na oštrinu vida ili centralnu retinalnu debljinu u bolesnika liječenih Lucentisom nije bio pod utjecajem istodobnog liječenja tiazolidindionima.
English: What Lucentis is used for
Croatian: Za što se Lucentis koristi
English: In both studies, subjects received a 0.5 mg ranibizumab PRN dosing regimen driven by individualised stabilisation criteria.
Croatian: U oba ispitivanja ispitanici su primali dozu od 0,5 mg ranibizumaba prema potrebi (p.p.) u skladu s individualnim kriterijima stabilizacije.
English: The usual dose of an injection is 0.02 ml (which contains 0.2 mg of active substance).
Croatian: Uobičajena doza injekcije je 0,02 ml (koja sadrži 0,2 mg djelatne tvari).
English: 1 pre-filled syringe of 0.165 ml.
Croatian: 1 napunjena štrcaljka od 0,165 ml.
English: The pre-filled syringe contains 0.165 ml of a sterile, clear, colourless to pale yellow aqueous solution.
Croatian: Napunjena štrcaljka sadrži 0,165 ml sterilne, bistre, bezbojne do blijedožute vodene otopine.
English: Before withdrawal, the outer part of the rubber stopper of the vial should be disinfected.
Croatian: Prije izvlačenja sadržaja bočice potrebno je dezinficirati vanjsku površinu gumenog čepa na bočici.
English: In wet AMD, in CNV, in PDR and in visual impairment due to DME or to macular oedema secondary to RVO the recommended dose for Lucentis is 0.5 mg given as a single intravitreal injection.
Croatian: Kod vlažnog AMD-a, kod CNV-a, kod PDR-a te poremećaja vida nastalog zbog DME-a ili makularnog edema posljedičnog RVO-u preporučena doza Lucentisa iznosi 0,5 mg u obliku jednokratne intravitrealne injekcije.
English: The adverse reactions experienced following administration of Lucentis in clinical trials are summarised in the table below.
Croatian: Nuspojave koje su se pojavile nakon primjene Lucentisa u kliničkim ispitivanjima sažete su u tablici u nastavku.
English: What Lucentis contains - The active substance is ranibizumab.
Croatian: Što Lucentis sadrži - Djelatna tvar je ranibizumab.
English: Other side effects which may occur following Lucentis treatment are described below: Common side effects
Croatian: Ostale nuspojave koje se mogu javiti uslijed liječenja Lucentisom opisane su u nastavku: Česte nuspojave
English: The mean number of injections given over 12 months was 5.8 in the ranibizumab arm versus 5.4 in those patients in the sham arm who were eligible to receive ranibizumab from Month 2 onwards.
Croatian: Srednji broj injekcija primijenjenih tijekom 12 mjeseci bio je 5,8 u skupini koja je primala ranibizumab u usporedbi s 5,4 u onih bolesnika koji su primali prividne injekcije i koji su mogli primati ranibizumab od 2. mjeseca nadalje.
English: In the sham arm 7 out of 59 patients did not receive any treatment with ranibizumab in the study eye during the 12-month period.
Croatian: U skupini s prividnim injekcijama, 7 od 59 bolesnika nije primilo nikakvu terapiju ranibizumabom u ispitivano oko tijekom 12-mjesečnog razdoblja.
English: VIAL + FILTER NEEDLE
Croatian: BOČICA + IGLA S FILTEROM
English: The filter needle should be discarded after withdrawal of the vial contents and should not be used for the intravitreal injection.
Croatian: Igla s filterom se ne smije koristiti za primjenu intravitrealne injekcije već se nakon izvlačenja sadržaja iz bočice treba baciti.
English: The long-term safety profile of ranibizumab observed in the 24-month studies is consistent with the known Lucentis safety profile.
Croatian: Dugoročni sigurnosni profil ranibizumaba uočen u 24-mjesečnim ispitivanjima u skladu je s poznatim sigurnosnim profilom Lucentisa.
English: 1x 0.23 ml vial
Croatian: 1x 0,23 ml bočica
English: The usual dose of an injection is 0.05 ml (which contains 0.5 mg of active substance).
Croatian: Uobičajena doza injekcije je 0,05 ml (koja sadrži 0,5 mg djelatne tvari).
English: In the phase III study D2301 (RESTORE), 345 patients were randomised in a 1:1:1 ratio to receive ranibizumab 0.5 mg monotherapy and sham laser photocoagulation, combined ranibizumab 0.5 mg and laser photocoagulation or sham injection and laser photocoagulation.
Croatian: U ispitivanju faze III D2301 (RESTORE), 345 bolesnika bilo je randomizirano u omjeru 1:1:1 na primanje ranibizumaba 0,5 mg u monoterapiji i prividne laserske fotokoagulacije, kombinacije ranibizumaba 0,5 mg i laserske fotokoagulacije ili prividne injekcije i laserske fotokoagulacije.
English: Serum ranibizumab concentrations in RVO patients were similar or slightly higher compared to those observed in neovascular AMD patients.
Croatian: Koncentracije ranibizumaba u serumu u bolesnika sa RVOom bile su slične ili malo više u usporedbi s onim zabilježenim u bolesnika s neovaskularnim AMDom.
English: Treatment is initiated with one injection per month until maximum visual acuity is achieved and/or there are no signs of disease activity i.e. no change in visual acuity and in other signs and symptoms of the disease under continued treatment.
Croatian: Liječenje započinje jednom injekcijom mjesečno sve dok se ne postigne maksimalna oštrina vida i/ili dok nema znakova aktivnosti bolesti tj. nema promjene u oštrini vida i u drugim znakovima i simptomima bolesti na kontinuiranoj terapiji.
English: Patients with renal impairment: No formal studies have been conducted to examine the pharmacokinetics of Lucentis in patients with renal impairment.
Croatian: Bolesnici s oštećenjem bubrega: nisu provedena formalna ispitivanja farmakokinetike Lucentisa u bolesnika s oštećenjem bubrega.
English: Intravitreal use.
Croatian: Intravitrealna upotreba.
English: Also contains: α,α-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections.
Croatian: Također sadrži: α,α-trehaloza dihidrat, histidinklorid hidrat, histidin, polisorbat 20, vodu za injekcije.
English: Intravitreous injections, including those with Lucentis, have been associated with endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract (see section 4.8).
Croatian: Primjena intravitrealnih injekcija, uključujući primjenu Lucentisa, bila je povezana s pojavom endoftalmitisa, intraokularne upale, regmatogene ablacije mrežnice, razderotine mrežnice i jatrogene traumatske katarakte (vidjeti dio 4.8).
English: These posterior segment changes diminished, and in some instances resolved, during the recovery period.
Croatian: Tijekom razdoblja oporavka te su se promjene u stražnjem segmentu smanjile ili su potpuno nestale u nekim slučajevima.
English: Treatment in adults is initiated with one injection per month until maximum visual acuity is achieved and/or there are no signs of disease activity i.e. no change in visual acuity and in other signs and symptoms of the disease under continued treatment.
Croatian: Liječenje u odraslih započinje jednom injekcijom mjesečno sve dok se ne postigne maksimalna oštrina vida i/ili dok nema znakova aktivnosti bolesti tj. nema promjene u oštrini vida i u drugim znakovima i simptomima bolesti na kontinuiranoj terapiji.
English: IA2
Croatian: Privremena izvješća: IA2
English: The solution is clear, colourless to pale yellow and aqueous.
Croatian: Otopina je bistra, bezbojna do blijedožuta i vodena.
English: Non-visual side effects include: Headache and joint pain.
Croatian: Nuspojave koje nisu povezane s vidom uključuju: glavobolju i bol u zglobovima.
English: Intravitreal use
Croatian: Intravitrealna upotreba
English: Cataract formation was observed in some animals after a relatively long period of intense inflammation, suggesting that the lens changes were secondary to severe inflammation.
Croatian: U nekih je životinja nakon razmjerno dugog razdoblja jake upale uočena pojava katarakte, što upućuje na zaključak da se promjene na leći javljaju kao sekundarna pojava nakon teške upale.
English: Other side effects in adults are described below:
Croatian: Ostale nuspojave u odraslih opisane su u nastavku:
English: Lucentis has not been studied in patients with hepatic impairment.
Croatian: Lucentis nije ispitivan u bolesnika s oštećenjem jetre.
English: The vial and filter needle are for single use only.
Croatian: Bočica i igla s filterom su samo za jednokratnu uporabu.
English: In BRIGHTER, ranibizumab 0.5 mg with adjunctive laser therapy demonstrated non-inferiority versus ranibizumab monotherapy from baseline to Month 24 (95% CI -2.8, 1.4).
Croatian: U ispitivanju BRIGHTER, ranibizumab 0,5 mg s dodatkom laserske terapije pokazao je neinferiornost u odnosu na monoterapiju ranibizumabom od početka do 24. mjeseca (95% CI -2,8 ; 1,4).
English: If you are considering stopping Lucentis treatment, please go to your next appointment and discuss this with your doctor.
Croatian: Ako razmišljate o prekidu liječenja Lucentisom, molimo da posjetite liječnika u prvom predviđenom terminu i o tome s njim porazgovarate.
English: - Inform your doctor if you have a prior history of eye conditions or eye treatments, or if you have had a stroke or experienced transient signs of stroke (weakness or paralysis of limbs or face, difficulty speaking or understanding).
Croatian: - Ukoliko ste imali očnu bolest ili liječenje oka, ili ako ste pretrpjeli moždani udar ili privremeno razvili njegove znakove (slabost ili kljenut udova ili lica, teškoće u govoru ili razumijevanju), o tome obavijestite svog liječnika.
English: Table 5 Outcomes at Month 12 in study D2301 (RESTORE) and at Month 36 in study D2301-E1 (RESTORE Extension)
Croatian: Tablica 5 Ishodi u 12. mjesecu u ispitivanju D2301 (RESTORE) te u 36. mjesecu u ispitivanju D2301-E1 (RESTORE Produžetak)
English: The estimated difference between ranibizumab and laser was 29.9% (95% CI: [20.0, 39.7]).
Croatian: Procijenjena razlika između ranibizumaba i lasera bila je 29,9% (95% CI: [20,0; 39,7]).
English: Group II Ranibizumab 0.5 mg “disease activity” (n=116)
Croatian: II. skupina Ranibizumab 0,5 mg „aktivnost bolesti“ (n=116)
English: • The treatment of visual impairment due to choroidal neovascularisation (CNV)
Croatian: • Liječenje poremećaja vida uzrokovanog neovaskularizacijom žilnice (CNV)
English: The symptoms you might experience are pain or increased discomfort in your eye, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision or increased sensitivity to light.
Croatian: Simptomi koje biste mogli osjetiti su bol ili povećana nelagoda u oku, pogoršanje crvenila oka, zamagljeni ili smanjeni vid, povećani broj malih čestica u vidnom polju ili povećana osjetljivost na svjetlost.
English: In CRYSTAL, patients with ischaemia present (N=53) or absent (N=300) and treated with ranibizumab monotherapy had a mean change from baseline of +15.0 and +11.5 letters, respectively.
Croatian: U ispitivanju CRYSTAL, bolesnici u kojih je ishemija bila prisutna (N=53) ili odsutna (N=300) i koji su bili liječeni monoterapijom ranibizumabom imali su srednju promjenu od +15,0 odnosno +11,5 slova u odnosu na početnu vrijednost.
English: In the ranibizumab-treated group, ≥2-step improvement in DRSS from baseline was observed in 58.5% (n=24) of eyes with baseline DME and 37.8% (n=56) of eyes without DME.
Croatian: U skupini liječenoj ranibizumabom, poboljšanje DRSS-a za ≥2 koraka u odnosu na početni bilo je opaženo u 58,5% (n=24) očiju s DME-om na početku te u 37,8% (n=56) očiju bez DME-a.
English: One-sided p<0.001 comparison with sham control b
Croatian: Jednostrani p<0,001 za usporedbu s prividnom kontrolom b
English: In wet AMD, the clinical safety and efficacy of Lucentis have been assessed in three randomised, double-masked, sham- or active-controlled studies of 24 months duration in patients with neovascular AMD.
Croatian: Kod vlažnog AMD-a, klinička sigurnost primjene i djelotvornost Lucentisa ispitivani su u tri randomizirana, dvostruko maskirana ispitivanja kontrolirana placebo postupkom (prividno dane injekcije) ili aktivnim lijekom u trajanju od 24 mjeseca u bolesnika s neovaskularnim AMD-om.
English: Lucentis and verteporfin photodynamic therapy in CNV secondary to PM There is no experience of concomitant administration of Lucentis and verteporfin.
Croatian: Fotodinamska terapija Lucentisom i verteporfinom u CNV-u posljedičnom PM-u Nema iskustava s istodobnom primjenom Lucentisa i verteporfina.
English: At year 1, 41.8% of eyes experienced a ≥2-step improvement in the DRSS when treated with ranibizumab (n=189) compared to 14.6% of eyes treated with PRP (n=199).
Croatian: Nakon 1 godine, u 41,8% očiju došlo je do poboljšanja za ≥2 koraka u DRSS-u kad su bila liječena ranibizumabom (n=189) u usporedbi s 14,6% očiju liječenih PRP-om (n=199).
English: Lucentis should be inspected visually for particulate matter and discoloration prior to administration.
Croatian: Lucentis treba prije primjene vizualno pregledati radi prisutnosti čestica i promjene boje.
English: Gain of ≥15 letters or BCVA ≥84 letters at Month 36 (%) Mean number of injections (Months 12-35)* p<0.0001 for comparisons of ranibizumab arms vs. laser arm. n in D2301-E1 (RESTORE Extension) is the number of patients with a value at both D2301 (RESTORE) baseline (Month 0) and at the Month 36 visit.
Croatian: Srednja promjena BCVA u 24. mjesecu (SD) Srednja promjena BCVA u 36. mjesecu (SD) Dobiveno ≥15 slova ili BCVA ≥84 slova u 36. mjesecu (%) Srednji broj injekcija (mjeseci 12-35)* p<0,0001 za usporedbe skupine koja je primala ranibizumab naspram skupine s laserskom terapijom. n u D2301-E1 (RESTORE Produžetak) označava broj bolesnika s vrijednošću na početku ispitivanja D2301 (RESTORE) (0. mjesec) i na posjetu u 36. mjesecu.
English: Please find information for babies born prematurely on the other side of this leaflet.
Croatian: Informacije za prijevremeno rođenu dojenčad potražite s druge strane ove upute.
English: Intravitreal injection-related reactions
Croatian: Reakcije povezane s intravitrealnim injekcijama
English: The excess volume should be expelled prior to injection.
Croatian: Višak volumena je potrebno izbaciti prije primjene injekcije.
English: Hepatic impairment: No formal studies have been conducted to examine the pharmacokinetics of Lucentis in patients with hepatic impairment.
Croatian: Oštećenje jetre: nisu provedena formalna ispitivanja farmakokinetike Lucentisa u bolesnika s oštećenjem jetre.
English: Non-ocular adverse reactions reported in more than one patient treated with ranibizumab 0.2 mg were nasopharyngitis, anaemia, cough, urinary tract infection and allergic reactions.
Croatian: Nuspojave koje nisu vezane uz oko a prijavljene su u više od jednog bolesnika liječenog ranibizumabom 0,2 mg bile su nazofaringitis, anemija, kašalj, infekcija mokraćnog sustava i alergijske reakcije.
English: This will expel the air and the excess solution and set the dose to 0.05 ml.
Croatian: Na taj način ćete izbaciti zrak i višak tekućine te podesiti dozu na 0,05 ml.
English: The extractable volume of one pre-filled syringe is 0.1 ml.
Croatian: Volumen jedne napunjene štrcaljke koji je moguće ekstrahirati iznosi 0,1 ml.
English: - The other ingredients are α,α-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections.
Croatian: - Drugi sastojci su α,α-trehaloza dihidrat, histidinklorid hidrat, histidin, polisorbat 20, voda za injekcije.
English: Clear, colourless to pale yellow aqueous solution.
Croatian: Bistra, bezbojna do blijedožuta vodena otopina.
English: The improvement of vision was accompanied by a reduction in central retinal thickness.
Croatian: Poboljšanje vida bilo je popraćeno smanjenjem centralne debljine mrežnice.
English: The pre-filled syringe is for single use only.
Croatian: Napunjena štrcaljka je samo za jednokratnu uporabu.
English: • The treatment of visual impairment due to diabetic macular oedema (DME)
Croatian: • Liječenje poremećaja vida uzrokovanog dijabetičkim makularnim edemom (DME)
English: In study FVF2587g (ANCHOR), 423 patients with predominantly classic CNV lesions were randomised in a 1:1:1 ratio to receive Lucentis 0.3 mg monthly, Lucentis 0.5 mg monthly or verteporfin PDT (at baseline and every 3 months thereafter if fluorescein angiography showed persistence or recurrence of vascular leakage).
Croatian: U ispitivanju FVF2587g (ANCHOR), 423 bolesnika s predominantno klasičnim CNV lezijama randomizirani su u omjeru 1:1:1 na primanje 0,3 mg Lucentisa mjesečno, 0,5 mg Lucentisa mjesečno ili verteporfin PDT (na početku te svaka 3 mjeseca nakon toga, ako je fluoresceinska angiografija pokazala da vaskularno propuštanje i dalje traje ili da se javio recidiv).
English: Visual side effects include: Bleeding in the back of the eye (retinal bleeding), bleeding in the eye or at the site of injection, and bloodshot eye (conjunctival bleeding).
Croatian: Nuspojave povezane s vidom uključuju: krvarenje u stražnjem dijelu oka (krvarenje mrežnice), krvarenje u oku ili na mjestu primjene injekcije, te krvni podljev oka (krvarenje konjunktive).
English: The long-term safety profile of ranibizumab observed in the 24-month extension study is consistent with the known Lucentis safety profile.
Croatian: Dugoročni sigurnosi profil ranibizumaba uočen u 24-mjesečnom produžetku ispitivnaja u skladu je s poznatim sigurnosnim profilom za Lucentis.
English: For treatment of preterm infants the low volume high accuracy syringe provided together with an injection needle (30G x ½″) in the VISISURE kit should be used (see also section 6.6).
Croatian: Za liječenje prijevremeno rođene dojenčadi mora se upotrijebiti precizna štrcaljka malog volumena koja se isporučuje s iglom za injekciju (30G x ½″) u kompletu VISISURE (vidjeti također dio 6.6).
English: • How to prepare for Lucentis treatment
Croatian: • Način pripreme bolesnika za liječenje Lucentisom
English: Remove syringe cap
Croatian: Uklonite zatvarač sa štrcaljke
English: One vial (type I glass) with a stopper (chlorobutyl rubber) containing 0.23 ml sterile solution and 1 blunt filter needle (18G x 1½″, 1.2 mm x 40 mm, 5 µm).
Croatian: Jedna bočica (staklo tipa I) s čepom (klorobutilna guma) koja sadrži 0,23 ml sterilne otopine i 1 tupa igla s filterom (18G x 1½″, 1,2 mm x 40 mm, 5 µm).
English: Key outcome measures are summarised in Table 1 and Figure 1.
Croatian: Ključni pokazatelji ishoda sažeto su prikazani u Tablici 1 i na Slici 1.
English: Note: Do not wipe the injection needle.
Croatian: Napomena: Iglu za injekciju nemojte brisati.
English: Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid and ocular surface should be administered prior to the injection, in accordance with local practice.
Croatian: Prije injekcije potrebno je primijeniti odgovarajuću anesteziju i topikalni baktericid širokog spektra za dezinfekciju kože oko oka, očnog kapka i površine oka, u skladu s lokalnom praksom.
English: - If you have any further questions, ask your baby's doctor.
Croatian: - Ako imate dodatnih pitanja, obratite se djetetovom liječniku.
English: Read all of this leaflet carefully before your baby is given this medicine because it contains important information for you.
Croatian: Vaše dijete primi ovaj lijek jer sadrži Vama važne podatke.
English: The most serious side effects in adults are described below:
Croatian: Najozbiljnije nuspojave u odraslih opisane su u nastavku:
English: How to store Lucentis
Croatian: Kako primjenjivati Lucentis
English: In the 405 DRSS gradable patients with moderate NPDR or better, a ≥2-step DRSS improvement was observed in 1.4% and 0.9% of the ranibizumab and laser groups, respectively.
Croatian: U 405 bolesnika s ocjenjivim DRSS-om s umjerenom ili lakšom NPDR, poboljšanje od ≥2 koraka u DRSS-u uočeno je u 1,4% bolesnika u skupini koja je liječena ranibizumabom, odnosno 0,9% bolesnika u skupini koja je liječena laserom.
English: Pre-filled syringe description
Croatian: Opis napunjene štrcaljke
English: The key outcome measures are summarised in Table 6.
Croatian: Ključne mjere ishoda sažete su u Tablici 6.
English: To expel the air bubble along with the excess medicinal product, slowly push the plunger until the edge below the dome of the rubber stopper is aligned with the black dosing line on the syringe (equivalent to 0.05 ml, i.e., 0.5 mg ranibizumab).
Croatian: Da biste izbacili mjehuriće zraka zajedno s viškom lijeka, polagano potisnite klip sve dok rub ispod kupole gumenog čepa ne bude u ravnini s crnom linijom oznake doze na štrcaljki (što odgovara količini od 0,05 ml, tj.
English: If you are considering stopping Lucentis treatment for your baby, please go to your next appointment and discuss this with your baby's doctor.
Croatian: Ako razmišljate o prekidu liječenja Vašeg djeteta Lucentisom, molimo da posjetite djetetovog liječnika u prvom predviđenom terminu i o tome s njim porazgovarate.
English: The study compared ranibizumab 0.5 mg intravitreal injections to standard treatment with PRP.
Croatian: Ispitivanje je uspoređivalo intravitrealne injekcije ranibizumaba 0,5 mg sa standardnim liječenjem PRP-om.
English: • The treatment of neovascular (wet) age-related macular degeneration (AMD)
Croatian: • Liječenje neovaskularne (vlažne) senilne makularne degeneracije (AMD)
English: Breast-feeding is not recommended during the use of Lucentis.
Croatian: Tijekom primjene Lucentisa dojenje se ne preporučuje.